$1.21
Insights on Biodesix Inc
Revenue is up for the last 4 quarters, 9.05M → 14.66M (in $), with an average increase of 14.6% per quarter
Netprofit is up for the last 5 quarters, -26.78M → -9.13M (in $), with an average increase of 31.6% per quarter
In the last 1 year, Iqvia Holdings Inc. has given 12.1% return, outperforming this stock by 47.4%
In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.4% return, outperforming this stock by 99.2%
2.48%
Downside
Day's Volatility :4.07%
Upside
1.63%
14.88%
Downside
52 Weeks Volatility :53.39%
Upside
45.25%
Period | Biodesix Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -37.95% | -0.7% | 0.0% |
6 Months | -28.82% | 6.6% | 0.0% |
1 Year | -35.29% | 3.7% | -1.5% |
3 Years | -93.59% | 14.0% | -21.8% |
Market Capitalization | 142.9M |
Book Value | $0.05 |
Earnings Per Share (EPS) | -0.64 |
Wall Street Target Price | 3.5 |
Profit Margin | -106.23% |
Operating Margin TTM | -46.67% |
Return On Assets TTM | -26.89% |
Return On Equity TTM | -414.09% |
Revenue TTM | 49.1M |
Revenue Per Share TTM | 0.6 |
Quarterly Revenue Growth YOY | 52.7% |
Gross Profit TTM | 24.1M |
EBITDA | -38.0M |
Diluted Eps TTM | -0.64 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.42 |
EPS Estimate Next Year | -0.32 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | -0.14 |
What analysts predicted
Upside of 189.26%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 20.4M | - |
Net Income | -26.2M | - |
Net Profit Margin | -128.06% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 24.6M | ↑ 20.16% |
Net Income | -31.4M | ↑ 19.83% |
Net Profit Margin | -127.71% | ↑ 0.35% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 45.6M | ↑ 85.55% |
Net Income | -36.5M | ↑ 16.32% |
Net Profit Margin | -80.06% | ↑ 47.65% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 54.5M | ↑ 19.64% |
Net Income | -44.5M | ↑ 21.95% |
Net Profit Margin | -81.61% | ↓ 1.55% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 38.2M | ↓ 29.89% |
Net Income | -80.4M | ↑ 80.73% |
Net Profit Margin | -210.37% | ↓ 128.76% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 49.1M | ↑ 28.46% |
Net Income | -52.1M | ↓ 35.13% |
Net Profit Margin | -106.23% | ↑ 104.14% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.1M | ↑ 1.43% |
Net Income | -16.8M | ↓ 16.15% |
Net Profit Margin | -151.15% | ↑ 31.7% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 9.6M | ↓ 13.5% |
Net Income | -26.8M | ↑ 59.55% |
Net Profit Margin | -278.79% | ↓ 127.64% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.1M | ↓ 5.75% |
Net Income | -17.1M | ↓ 36.1% |
Net Profit Margin | -189.0% | ↑ 89.79% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.9M | ↑ 31.1% |
Net Income | -13.4M | ↓ 21.97% |
Net Profit Margin | -112.5% | ↑ 76.5% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.5M | ↑ 13.64% |
Net Income | -10.9M | ↓ 18.02% |
Net Profit Margin | -81.16% | ↑ 31.34% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.7M | ↑ 8.72% |
Net Income | -9.1M | ↓ 16.53% |
Net Profit Margin | -62.31% | ↑ 18.85% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 39.1M | - |
Total Liabilities | 237.1M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 41.6M | ↑ 6.6% |
Total Liabilities | 270.2M | ↑ 13.95% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 121.1M | ↑ 190.8% |
Total Liabilities | 79.9M | ↓ 70.42% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 76.1M | ↓ 37.15% |
Total Liabilities | 56.4M | ↓ 29.45% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 92.9M | ↑ 22.09% |
Total Liabilities | 72.3M | ↑ 28.26% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 99.1M | ↑ 6.66% |
Total Liabilities | 94.5M | ↑ 30.73% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 63.2M | ↓ 15.99% |
Total Liabilities | 66.1M | ↓ 2.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 92.9M | ↑ 47.01% |
Total Liabilities | 72.3M | ↑ 9.38% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 80.8M | ↓ 13.04% |
Total Liabilities | 76.2M | ↑ 5.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 77.6M | ↓ 3.92% |
Total Liabilities | 84.6M | ↑ 10.98% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 86.8M | ↑ 11.8% |
Total Liabilities | 88.2M | ↑ 4.27% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 99.1M | ↑ 14.18% |
Total Liabilities | 94.5M | ↑ 7.12% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.7M | - |
Investing Cash Flow | -617.0K | - |
Financing Cash Flow | 19.0M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.7M | ↑ 22.91% |
Investing Cash Flow | -1.9M | ↑ 203.4% |
Financing Cash Flow | 23.0M | ↑ 20.7% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.4M | ↓ 1.66% |
Investing Cash Flow | -2.9M | ↑ 56.36% |
Financing Cash Flow | 81.1M | ↑ 253.17% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.2M | ↑ 32.09% |
Investing Cash Flow | -2.5M | ↓ 12.98% |
Financing Cash Flow | 1.3M | ↓ 98.44% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -45.0M | ↑ 59.35% |
Investing Cash Flow | -3.5M | ↑ 38.75% |
Financing Cash Flow | 58.9M | ↑ 4565.77% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.3M | ↑ 7.68% |
Investing Cash Flow | -815.0K | ↑ 114.47% |
Financing Cash Flow | -2.3M | ↓ 110.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -11.9M | ↑ 15.65% |
Investing Cash Flow | -2.0M | ↑ 143.8% |
Financing Cash Flow | 41.8M | ↓ 1947.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.7M | ↓ 35.67% |
Investing Cash Flow | -6.5M | ↑ 225.72% |
Financing Cash Flow | -2.4M | ↓ 105.79% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 937.0K | ↓ 112.19% |
Investing Cash Flow | -6.5M | ↑ 0.0% |
Financing Cash Flow | -2.3M | ↓ 3.76% |
Sell
Neutral
Buy
Biodesix Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Biodesix Inc | -12.32% | -28.82% | -35.29% | -93.59% | -90.55% |
Idexx Laboratories, Inc. | -9.73% | 12.44% | -0.8% | -9.52% | 118.88% |
Agilent Technologies Inc. | -7.9% | 23.88% | -3.2% | 0.79% | 76.64% |
Thermo Fisher Scientific, Inc. | -5.65% | 17.12% | -6.43% | 12.22% | 110.66% |
Danaher Corp. | -4.8% | 16.89% | -6.54% | -1.07% | 88.84% |
Iqvia Holdings Inc. | -10.49% | 20.27% | 12.09% | 5.1% | 70.85% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Biodesix Inc | NA | NA | NA | -0.42 | -4.14 | -0.27 | NA | 0.05 |
Idexx Laboratories, Inc. | 48.76 | 48.76 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 33.53 | 33.53 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 35.85 | 35.85 | 2.81 | 21.56 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 42.54 | 42.54 | 3.13 | 7.62 | 0.08 | 0.04 | 0.0 | 72.36 |
Iqvia Holdings Inc. | 31.74 | 31.74 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Biodesix Inc | Buy | $142.9M | -90.55% | NA | -106.23% |
Idexx Laboratories, Inc. | Buy | $40.7B | 118.88% | 48.76 | 23.08% |
Agilent Technologies Inc. | Buy | $41.1B | 76.64% | 33.53 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $211.7B | 110.66% | 35.85 | 13.99% |
Danaher Corp. | Buy | $178.0B | 88.84% | 42.54 | 19.94% |
Iqvia Holdings Inc. | Buy | $42.1B | 70.85% | 31.74 | 9.06% |
Birchview Capital, LP
AIGH Capital Management, LLC
Worth Venture Partners, LLC
Essex Investment Management Company, LLC
Wells Fargo & Co
Vanguard Group Inc
Biodesix Inc’s price-to-earnings ratio stands at None
Read Morebiodesix develops and commercializes blood-based molecular diagnostic tests that advance the standard of care in oncology. our diagnostics help patients and their doctors make more informed decisions about treatment based on a patient's unique molecular profile. we're advancing precision medicine by helping physicians provide the right patient with the right treatment at the right time, and move patients to optimal treatment faster. we partner with pharmaceutical companies to develop tests that accelerate pipelines and bring effective therapies to market. our two commercialized tests, veristrat® & genestrat™, offer results in 72 hours. no tissue is required.
Organization | Biodesix Inc |
Employees | 217 |
CEO | Mr. Scott Hutton |
Industry | Health Services |